• Lydia Estanislao, Kay Carter, Justin McArthur, Richard Olney, David Simpson, and Lidoderm-HIV Neuropathy Group.
• Department of Neurology and Clinical Neurophysiology, Mount Sinai Medical Center, New York, NY 10029, USA.
• J. Acquir. Immune Defic. Syndr. 2004 Dec 15;37(5):1584-6.

ObjectiveTo investigate the analgesic efficacy and safety of 5% lidocaine gel in painful HIV-associated distal sensory polyneuropathy (DSP).BackgroundPainful DSP, the most common neurologic complication in HIV infection, is difficult to treat. Lidocaine 5% gel was effective in alleviating neuropathic pain in an open-label study of HIV DSP.MethodsIn a double-blind, placebo-controlled, crossover, multi-center study, 64 subjects were randomized to receive 5% lidocaine or vehicle gel for 2 weeks (phase A). A washout period of 2 weeks was followed by a crossover to the alternate agent for another 2 weeks (phase B). The primary outcome was difference in average pain scores (Gracely pain scale) between the 2 groups during the second week of each treatment period. Secondary outcomes included differential effect of the first treatment, difference in global pain relief, and pain response by neurotoxin exposure.ResultsThe baseline pain scores of the 2 groups were similar. The average pain scores during the second week of each phase of the lidocaine gel group did not differ from those of the placebo group (phase A: lidocaine 1.09, placebo 1.15; phase B: lidocaine 1.16, placebo 1.10). There also was no difference noted in secondary outcomes. The pain responses of lidocaine gel-treated subjects with current exposure to neurotoxic antiretrovirals (1.18) did not differ compared with those without (1.10) (P = 0.358). There were no significant adverse effects.ConclusionLidocaine 5% gel is a safe but ineffective agent in the treatment of pain in HIV-associated DSP.

18 keywords...

hide…